CA-CONVIVA
Conviva, the leader in global streaming media intelligence, released its quarterly State of Streaming report for Q3 2020 today, showing a 57% year over year increase in overall viewing time, continuing the trend of multiple quarters of strong streaming growth. The report also uncovered new streaming trends including the long-awaited return of advertisers and the increasing battle between smart TVs and connected TV devices such as Roku.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201029005174/en/
“Streaming has exploded in the past year as illustrated by content like the NFL which saw 41% growth on streaming and remained relatively flat on linear TV,” said Bill Demas, CEO, Conviva. “As a result, we are seeing more investment in streaming services, advertisers shifting to streaming platforms and consumers adopting streaming-enabled devices and TVs at a rapid pace.”
Ad Demand Shows Signs of Recovery While Quality Improves
Unlike Q2 2020 when ad demand dropped dramatically due to the pandemic and lack of live sports, Q3 saw the global reemergence of ad demand, with a 22% increase in impressions owing to a 14% increase in ad attempts and a 22% decrease in failed ad attempts. Ad quality also improved in Q3, with time spent waiting for ads to buffer down 28%, and an 11% increase in picture quality.
Smart TVs on the Rise
Connected TV devices, such as Roku, Amazon Fire TV, Apple TV and Chromecast, continued to dominate streaming viewership in Q3 with 55% share of global viewing time. However, for the first time, connected TV devices did not keep pace with overall streaming growth (55% vs 57%), demonstrating an uncharacteristic falter in the category.
This slower growth can be attributed to more viewers streaming within their TV’s native app rather than via an external device. In fact, smart TVs like Samsung, LG and Vizio grew significantly faster than all other devices in Q3, up 200% in viewing time. With this skyrocketing growth, smart TVs nearly doubled share over the past year, up to 14.8% from 7.7% the previous Q3.
Roku still remained the market leader among connected TV devices, capturing nearly half of the total connected TV viewing time in the quarter at 47.7% share. Amazon Fire TV finished a distant second with 27.6%.
Sunday Streaming – NFL Tackles Digital
The number of NFL fans watching games via streaming increased 41% year over year. Daytime games saw the largest increase in Q3, up 63%, with nearly 70% of viewing taking place on a big screen. By contrast, primetime games captured a more modest 32% increase in viewing time year over year in Q3 2020.
TVs continue to dominate NFL viewing, with TV commanding 67% of all NFL viewing while mobile captured 13% and PC just 6% of NFL viewing time in Q3 2020.
On social media, North American sports leagues reached a new height in September with total engagements up 252% across the region’s sports leagues including the NBA, NFL, NHL, MLB, and MLS as compared to their low in June. The two largest players, the NBA and the NFL, tell two stories, with NFL teams able to exceed total engagement levels from January, while NBA teams have not yet recovered to pre-pandemic levels of engagement. NFL teams likely fared better during their return as they produced more content in September than any other month during the year, leading them to their most successful month of the year in engagements.
Methodology
Data for Conviva’s State of Streaming report was primarily collected from Conviva’s proprietary sensor technology currently embedded in three billion streaming video applications, measuring in excess of 500 million unique viewers watching 150 billion streams per year with 1.5 trillion real-time transactions per day across more than 180 countries. Year-over-year comparisons were normalized at the customer level for accurate representations of industry growth. The social data consists of data from over 1360 accounts, over 29 million posts, 4.8 million videos, 183 billion video views and over 41 billion engagements across Facebook, Twitter, Instagram and YouTube.
About Conviva
Conviva is the leader in streaming media intelligence, powered by its real-time platform. More than 250 industry leaders and brands – including CBS, CCTV, DAZN, Disney+, HBO Max, Hulu, Sky, Sling TV, TED, Univision and WarnerMedia – rely on Conviva to maximize their consumer engagement, deliver the quality experiences viewers expect and drive revenue growth. With a global footprint of more than 500 million unique viewers watching 150 billion streams per year across 3 billion applications streaming on devices, Conviva offers streaming providers unmatched scale for continuous video measurement, intelligence and benchmarking across every stream, every screen, every second.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201029005174/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alpega Group Completes Leadership Succession Plan Appointing Daniel Cohen New CEO8.1.2026 10:03:00 CET | Press release
Alpega Group, a leading pan-European provider of an end-to-end transportation and logistics platform, today announced a planned leadership transition. After a successful tenure as Chief Executive Officer, Todd DeLaughter will be retiring, stepping down from his role and transitioning to a Board Advisor role for the company. The Board of Directors has appointed Daniel Cohen as the incoming CEO, effective January 1st, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108528648/en/ Daniel Cohen, CEO Alpega Daniel Cohen brings three decades of experience leading B2B SaaS businesses through periods of change, scale, and value realization. Most recently, as CEO of PayU, he led a full financial, operational, and cultural transformation returning the business to sustained profitable growth. He subsequently steered the company through a highly complex, multi-jurisdictional process that culminated in the successful sale to Rapyd
FPT Named Sitecore’s First Global Partner Under Global Elite Reseller Program8.1.2026 09:00:00 CET | Press release
Global IT Corporation FPT announced its appointment as the inaugural Global Elite Reseller under a new initiative from Sitecore that expands upon its successful Global Reseller Program. The Global Elite Reseller Program follows the launch of SitecoreAI, the next-generation digital experience platform that puts artificial intelligence at the center of marketing, unifying content, data, and personalization in one composable platform so organizations can reach, engage, and serve their audience across digital channels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107425261/en/ Representatives from FPT and Sitecore at the Global Elite Reseller signing ceremony. Under the agreement, FPT will hold exclusive reseller rights in Vietnam and non-exclusive rights across select markets in Asia and the Middle East, taking SitecoreAI to market and showing how it helps teams plan, create, and optimize digital experiences using AI as cu
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 08:00:00 CET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release
FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release
The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom